Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2012 5
2013 2
2014 2
2015 4
2016 5
2017 4
2018 5
2019 8
2020 3
2021 4
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
CXCR6 expressing T cells: Functions and role in the control of tumors.
Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E, Tartour E. Mabrouk N, et al. Among authors: fabre e. Front Immunol. 2022 Oct 12;13:1022136. doi: 10.3389/fimmu.2022.1022136. eCollection 2022. Front Immunol. 2022. PMID: 36311728 Free PMC article. Review.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Immunotherapy for Solid Tumors.
de Saint Basile H, Maaradji Z, Fabre E. de Saint Basile H, et al. Among authors: fabre e. Cancers (Basel). 2023 Mar 8;15(6):1646. doi: 10.3390/cancers15061646. Cancers (Basel). 2023. PMID: 36980532 Free PMC article.
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarrán-Artahona V, Dall'Olio F, Soldato D, Hendriks L, Nana FA, Tonneau M, Lopez-Castro R, Nadal E, Kazandjian S, Muanza T, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Rochand A, Besse B, Routy B, Mezquita L. Auclin E, et al. Among authors: fabre e. Lung Cancer. 2023 Apr;178:116-122. doi: 10.1016/j.lungcan.2023.02.002. Epub 2023 Feb 4. Lung Cancer. 2023. PMID: 36812760
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.
Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H. Legras A, et al. Among authors: fabre e. Cancers (Basel). 2017 Aug 3;9(8):101. doi: 10.3390/cancers9080101. Cancers (Basel). 2017. PMID: 28771186 Free PMC article. Review.
Safety and efficacy of immunotherapy according to the age threshold of 80 years.
Mebarki S, Pamoukdjian F, Pierro M, Poisson J, Baldini C, Widad Lahlou, Taieb J, Fabre E, Canoui-Poitrine F, Oudard S, Paillaud E. Mebarki S, et al. Among authors: fabre e. Bull Cancer. 2023 May;110(5):570-580. doi: 10.1016/j.bulcan.2023.02.010. Epub 2023 Mar 7. Bull Cancer. 2023. PMID: 36894391 Review.
A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F, Fabre E, Gibault L, Laurent-Puig P, Mouillet-Richard S, Legras A, Blons H. Garinet S, et al. Among authors: fabre e. J Transl Med. 2023 May 15;21(1):324. doi: 10.1186/s12967-023-04086-7. J Transl Med. 2023. PMID: 37189151 Free PMC article.
48 results